Post-Treatment Controllers: Role in HIV “Cure” Research

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Current HIV/AIDS Reports

• Publication date

  2016-01-19

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s11904-016-0296-xPMID 26781112
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• How Often does Treatment of Primary HIV Lead to Post-Treatment Control?

  2015cited by this paper
• Broad CTL response is required to clear latent HIV-1 due to dominance of escape mutations

  2015cited by this paper
• Viremic relapse after HIV-1 remission in a perinatally infected child.

  2015cited by this paper
• A low HIV-DNA level in peripheral blood mononuclear cells at antiretroviral treatment interruption predicts a higher probability of maintaining viral control

  2015cited by this paper
• Post-treatment control of HIV infection

  2015cited by this paper
• No evidence of posttreatment control after early initiation of antiretroviral therapy

  2015cited by this paper
• Intensive five-drug antiretroviral therapy regimen versus standard triple-drug therapy during primary HIV-1 infection (OPTIPRIM-ANRS 147): a randomised, open-label, phase 3 trial.

  2015cited by this paper
• Combined ART started during acute HIV infection protects central memory CD4+ T cells and can induce remission.

  2015cited by this paper
• The need for treatment interruption studies and biomarker identification in the search for an HIV cure.

  2015cited by this paper
• Immunological biomarkers predict HIV-1 viral rebound after treatment interruption

  2015cited by this paper
• Markers of HIV reservoir size and immune activation after treatment in acute HIV infection with and without raltegravir and maraviroc intensification

  2015cited by this paper
• The effect of timing of antiretroviral therapy on CD4+ T-cell reconstitution in the intestine of HIV-infected patients

  2015cited by this paper
• Impact of the Timing of Initiation of Antiretroviral Therapy During Primary HIV-1 Infection on the Decay of Cell-Associated HIV-DNA.

  2015cited by this paper
• Rapid Seeding of the Viral Reservoir Prior to SIV Viremia in Rhesus Monkeys

  2014cited by this paper
• A Randomized Open-Label Study of 3- Versus 5-Drug Combination Antiretroviral Therapy in Newly HIV-1–Infected Individuals

  2014cited by this paper
• Early initiation of combined antiretroviral therapy preserves immune function in the gut of HIV-infected patients

  2014cited by this paper
• Limited HIV Infection of Central Memory and Stem Cell Memory CD4+ T Cells Is Associated with Lack of Progression in Viremic Individuals

  2014cited by this paper
• Corrections: Predicting the outcomes of treatment to eradicate the latent reservoir for HIV-1 (Proc Natl Acad Sci USA (2014) 111, (13475-13480) doi: 10.1073/pnas.1406663111)

  2014cited by this paper
• Hospitalization Rates and Reasons Among HIV Elite Controllers and Persons With Medically Controlled HIV Infection.

  2014cited by this paper
• How a single patient influenced HIV research--15-year follow-up.

  2014cited by this paper
• Predicting the outcomes of treatment to eradicate the latent reservoir for HIV-1

  2014cited by this paper
• Initiation of ART during Early Acute HIV Infection Preserves Mucosal Th17 Function and Reverses HIV-Related Immune Activation

  2014cited by this paper
• HIV-1 DNA predicts disease progression and post-treatment virological control

  2014cited by this paper
• Long-Term Antiretroviral Treatment Initiated at Primary HIV-1 Infection Affects the Size, Composition, and Decay Kinetics of the Reservoir of HIV-1-Infected CD4 T Cells

  2014cited by this paper
• Duration of HIV-1 Viral Suppression on Cessation of Antiretroviral Therapy in Primary Infection Correlates with Time on Therapy

  2013cited by this paper
• Prospective Antiretroviral Treatment of Asymptomatic, HIV-1 Infected Controllers

  2013cited by this paper
• Unravelling the mechanisms of durable control of HIV-1

  2013cited by this paper
• Post-Treatment HIV-1 Controllers with a Long-Term Virological Remission after the Interruption of Early Initiated Antiretroviral Therapy ANRS VISCONTI Study

  2013cited by this paper
• Effect of antiretroviral therapy on HIV reservoirs in elite controllers.

  2013cited by this paper
• Short-course antiretroviral therapy in primary HIV infection.

  2013cited by this paper
• Long-term antiretroviral therapy initiated during primary HIV-1 infection is key to achieving both low HIV reservoirs and normal T cell counts.

  2013cited by this paper
• Antiretroviral therapy initiated within 6 months of HIV infection is associated with lower T-cell activation and smaller HIV reservoir size.

  2013cited by this paper
• Immune activation and HIV persistence: implications for curative approaches to HIV infection

  2013cited by this paper
• Absence of detectable HIV-1 viremia after treatment cessation in an infant.

  2013cited by this paper
• Immunovirologic control 24 months after interruption of antiretroviral therapy initiated close to HIV seroconversion.

  2013cited by this paper
• Immune and Viral Correlates of “Secondary Viral Control” after Treatment Interruption in Chronically HIV-1 Infected Patients

  2012cited by this paper
• Integrated HIV DNA accumulates prior to treatment while episomal HIV DNA records ongoing transmission afterwards

  2012cited by this paper
• Hiv-1 Control after Transient Antiretroviral Treatment Initiated in Primary Infection: Role of Patient Characteristics and Effect of Therapy

  2012cited by this paper
• Immunovirologic control 24 months after interruption of antiretroviral therapy initiated close to HIV seroconversion.

  2012cited by this paper
• Immediate antiviral therapy appears to restrict resting CD4+ cell HIV-1 infection without accelerating the decay of latent infection

  2012cited by this paper
• Immune responses driven by protective human leukocyte antigen alleles from long-term nonprogressors are associated with low HIV reservoir in central memory CD4 T cells.

  2012cited by this paper
• Low levels of SIV infection in sooty mangabey central-memory CD4+ T-cells is associated with limited CCR5 expression

  2011cited by this paper
• Rebound of plasma viremia following cessation of antiretroviral therapy despite profoundly low levels of HIV reservoir: implications for eradication.

  2011cited by this paper
• A randomized, controlled trial of raltegravir intensification in antiretroviral-treated, HIV-infected patients with a suboptimal CD4+ T cell response.

  2011cited by this paper
• Alterations of the B-Cell Response by HIV-1 Replication

  2011cited by this paper
• Elite Suppressors Harbor Low Levels of Integrated HIV DNA and High Levels of 2-LTR Circular HIV DNA Compared to HIV+ Patients On and Off HAART

  2011cited by this paper
• Epidemiology and clinical characteristics of elite controllers

  2011influential reference
• Prolonged control of replication-competent dual- tropic human immunodeficiency virus-1 following cessation of highly active antiretroviral therapy

  2011cited by this paper
• Restriction of HIV-1 replication in macrophages and CD4+ T cells from HIV controllers.

  2011cited by this paper
• Tryptophan Catabolism by Indoleamine 2,3-Dioxygenase 1 Alters the Balance of TH17 to Regulatory T Cells in HIV Disease

  2010cited by this paper
• Rapid Progressing Allele HLA-B35 Px Restricted Anti-HIV-1 CD8+ T Cells Recognize Vestigial CTL Epitopes

  2010cited by this paper
• Damaged Intestinal Epithelial Integrity Linked to Microbial Translocation in Pathogenic Simian Immunodeficiency Virus Infections

  2010cited by this paper
• HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects

  2010cited by this paper
• Rebound of plasma viremia following cessation of antiretroviral therapy despite profoundly low levels of HIV reservoir: implications for eradication

  2010cited by this paper
• B cells in early and chronic HIV infection: evidence for preservation of immune function associated with early initiation of antiretroviral therapy.

  2010cited by this paper
• Timing of HAART defines the integrity of memory B cells and the longevity of humoral responses in HIV-1 vertically-infected children

  2009cited by this paper
• Clinical outcomes of elite controllers, viremic controllers, and long-term nonprogressors in the US Department of Defense HIV natural history study.

  2009cited by this paper
• HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation

  2009cited by this paper
• HLA-B*35-Px–mediated acceleration of HIV-1 infection by increased inhibitory immunoregulatory impulses

  2009cited by this paper
• Spontaneous control of viral replication during primary HIV infection: when is "HIV controller" status established?

  2009cited by this paper
• Dynamics of total, linear nonintegrated, and integrated HIV-1 DNA in vivo and in vitro.

  2008cited by this paper
• Evidence for Persistent Low-Level Viremia in Individuals Who Control Human Immunodeficiency Virus in the Absence of Antiretroviral Therapy

  2008cited by this paper
• Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy.

  2008cited by this paper
• Decay of the HIV reservoir in patients receiving antiretroviral therapy for extended periods: implications for eradication of virus.

  2007cited by this paper
• Human immunodeficiency virus controllers: mechanisms of durable virus control in the absence of antiretroviral therapy.

  2007cited by this paper
• Innate partnership of HLA-B and KIR3DL1 subtypes against HIV-1

  2007cited by this paper
• Microbial translocation is a cause of systemic immune activation in chronic HIV infection

  2006cited by this paper
• Microbial translocation is a cause of systemic immune activation in chronic HIV infection

  2006cited by this paper
• CD4+ count-guided interruption of antiretroviral treatment.

  2006cited by this paper
• Massive infection and loss of memory CD4+ T cells in multiple tissues during acute SIV infection

  2005cited by this paper
• Effect of treatment, during primary infection, on establishment and clearance of cellular reservoirs of HIV-1.

  2005cited by this paper
• CD4+ T Cell Depletion during all Stages of HIV Disease Occurs Predominantly in the Gastrointestinal Tract

  2004cited by this paper
• Severe CD4+ T-Cell Depletion in Gut Lymphoid Tissue during Primary Human Immunodeficiency Virus Type 1 Infection and Substantial Delay in Restoration following Highly Active Antiretroviral Therapy

  2003cited by this paper
• Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells

  2003cited by this paper
• Nonpathogenic SIV infection of sooty mangabeys is characterized by limited bystander immunopathology despite chronic high-level viremia.

  2003cited by this paper
• Human Immunodeficiency Virus Type 1 (HIV-1)-Specific CD8+-T-Cell Responses for Groups of HIV-1-Infected Individuals with Different HLA-B*35 Genotypes

  2002cited by this paper
• Effect of a single amino acid change in MHC class I molecules on the rate of progression to AIDS.

  2001cited by this paper
• Early highly active antiretroviral therapy for acute HIV-1 infection preserves immune function of CD8+ and CD4+ T lymphocytes.

  2000cited by this paper

• Boosting SIV-specific CD8+ T cell responses prior to ART interruption extends time to SIVmac239 rebound.

  2026cites this paper
• HIV controllers: hope for a functional cure

  2025cites this paper
• Plasma, Intracellular and Lymph node Antiretroviral Concentrations and HIV DNA Change During Primary HIV Infection: Results from the INACTION P25 Study.

  2024cites this paper
• Irreversible Loss of HIV-1 Proviral Competence in Myeloid Cells upon Suppression of NF-κB Activity

  2022cites this paper
• Cure and Long-Term Remission Strategies.

  2022cites this paper
• Natural Killer Cell Receptors and Ligands Are Associated With Markers of HIV-1 Persistence in Chronically Infected ART Suppressed Patients

  2022cites this paper
• Long-term antiretroviral therapy initiated in acute HIV infection prevents residual dysfunction of HIV-specific CD8+ T cells

  2022cites this paper
• Towards a molecular profile of antiretroviral therapy-free HIV remission

  2022cites this paper
• Impact of Analytical Treatment Interruption on Burden and Diversification of HIV Peripheral Reservoir: A Pilot Study

  2021cites this paper
• In Vivo Dynamics of the Latent Reservoir for HIV-1: New Insights and Implications for Cure.

  2021cites this paper
• Predicting Post-treatment HIV Remission: Does Size of the Viral Reservoir Matter?

  2021cites this paper
• Early exposure to broadly neutralizing antibodies may trigger a dynamical switch from progressive disease to lasting control of SHIV infection

  2020cites this paper
• Pre-existing resistant proviruses can compromise maintenance of remission by VRC01 in chronic HIV-1 infection

  2020cites this paper
• Non-invasive plasma glycomic and metabolic biomarkers of post-treatment control of HIV

  2020cites this paper
• Pre-existing resistance in the latent reservoir can compromise VRC01 therapy during chronic HIV-1 infection

  2020cites this paper
• Block-And-Lock: New Horizons for a Cure for HIV-1

  2020cites this paper
• Title: Non-Invasive Plasma Glycomic and Metabolic Biomarkers of Post-treatment Control of HIV Short title: Plasma Biomarkers of Post-treatment HIV Control

  2020cites this paper
• Towards multiscale modeling of the CD8+ T cell response to viral infections

  2019cites this paper
• Broadly neutralizing anti-HIV-1 monoclonal antibodies in the clinic

  2019cites this paper
• Effects of 24-week Toll-like receptor 9 agonist treatment in HIV type 1+ individuals.

  2019cites this paper
• Early exposure to broadly neutralizing antibodies triggers a switch from progressive disease to lasting control of SHIV infection

  2019cites this paper
• Effects of 24 Week Toll -Like Receptor 9 Agonist Treatment in HIV-1+ Individuals: a single-arm, phase 1B/2A trial

  2019cites this paper
• Latent HIV dynamics and implications for sustained viral suppression in the absence of antiretroviral therapy

  2018cites this paper
• Long-term remission despite clonal expansion of replication-competent HIV-1 isolates.

  2018cites this paper
• HIV-1 proviral landscapes distinguish posttreatment controllers from noncontrollers

  2018cites this paper
• Combating the HIV reservoirs

  2018cites this paper
• Post-treatment controllers after treatment interruption in chronically HIV-infected patients

  2018cites this paper
• Multidisciplinary analysis of HIV-1 elite controllers

  2018cites this paper
• Harnessing Antibody-Dependent Cellular Cytotoxicity To Control HIV-1 Infection.

  2018cites this paper
• Post-treatment HIV controllers or spontaneous controllers in disguise?

  2017cites this paper
• Insights into the Impact of CD8+ Immune Modulation on Human Immunodeficiency Virus Evolutionary Dynamics in Distinct Anatomical Compartments by Using Simian Immunodeficiency Virus-Infected Macaque Models of AIDS Progression

  2017cites this paper
• Uptake of HIV Pre-Exposure Prophylaxis (PrEP) in a National Cohort of Gay and Bisexual Men in the United States

  2017cites this paper
• Letter

  2017cites this paper
• On the way to find a cure: Purging latent HIV‐1 reservoirs

  2017cites this paper
• Cytokines Elevated in HIV Elite Controllers Reduce HIV Replication In Vitro and Modulate HIV Restriction Factor Expression

  2017cites this paper